ACBM — Acro Biomedical Co Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4453.82% | ||
| Return on Equity | -3312.23% | ||
| Operating Margin | -4206.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.01 | 1.35 | 0.69 | 1.2 | 0.66 | n/a | n/a | 5.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acro Biomedical Co., Ltd. is principally engaged in the business of the sale of cordyceps related products. The Company is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The Company's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The Company is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. It sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 24th, 2014
- Public Since
- June 23rd, 2016
- No. of Shareholders
- 186
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 60,042,000
- Address
- 12175 Visionary Way Ste 1160, FISHERS, 46038-3069
- Web
- Phone
- +1 3172866788
- Auditors
- Prager Metis CPAs LLC
Upcoming Events for ACBM
Similar to ACBM
Adia Nutrition
Pink Sheets on Nasdaq
African Agriculture Holdings
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
FAQ
As of Today at 19:19 UTC, shares in Acro Biomedical Co are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Acro Biomedical Co last closed at $0.00 and the price had moved by -99.97% over the past 365 days. In terms of relative price strength the Acro Biomedical Co share price has underperformed the S&P500 Index by -99.97% over the past year.
There is no consensus recommendation for this security.
Find out moreAcro Biomedical Co does not currently pay a dividend.
Acro Biomedical Co does not currently pay a dividend.
Acro Biomedical Co does not currently pay a dividend.
To buy shares in Acro Biomedical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Acro Biomedical Co had a market capitalisation of .
Here are the trading details for Acro Biomedical Co:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACBM
Based on an overall assessment of its quality, value and momentum Acro Biomedical Co is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acro Biomedical Co. Over the past six months, its share price has underperformed the S&P500 Index by -99.31%.
As of the last closing price of $0.00, shares in Acro Biomedical Co were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Acro Biomedical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Acro Biomedical Co's management team is headed by:
- Pao-Chi Chu - PRE